Drugs / Recombinant Interferon Alpha
Recombinant Interferon Alpha
Trials 0
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05395507 Comparator | Jun 2022 → Mar 2025 | essential thrombocythemia | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| Phase 2 | NCT04226950 Comparator | Jan 2020 → Oct 2024 | essential thrombocythemia | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04501783 Comparator | May → Jul 2020 | COVID-19 | R-Pharm | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Interferon Alpha | “umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine” NCT04501783 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Interferon Alpha” NCT04226950 ↗ |
| Route | Intranasal | “intranasal recombinant interferon alpha” NCT04501783 ↗ |